Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

nths, a promising early result. Patient follow-up in the trial is continuing.

"The data released today continues to reinforce the positive results seen across the five cancer trials to date assessing the potential of bavituximab in different treatment combinations across multiple tumor types," said Steven W. King, president and CEO of Peregrine. "We believe this data in aggregate shows the broad potential of this novel therapeutic compound for the treatment of solid tumors. We look forward to reporting further results from our ongoing bavituximab studies and to providing more details on future clinical development plans as they are finalized over the coming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 192,370 U.S. women will be diagnosed with breast cancer in 2009 and 40,170 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab acts by binding to externalized PS on tumor blood vessels and inducing immune cell-mediated destruction of these blood vessels. It also restores the immune system's ability to recognize and resp
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... 04, 2015 Research ... addition of Jain PharmaBiotech,s new report "Animal ... their offering. This report describes and ... medicine and pharmaceuticals as well as improvement in ... in the application of biotechnology to manage genetic ...
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:8/4/2015)... ... 2015 , ... Worldwide Power Products acquires new assets, certifying ... in Texas. Effective July 1st of this year, Worldwide Power Products acquired operations ... the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 generators in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about ... Renew Man™ is standing up as a voice of authority for men seeking accurate ... aging industry with special experience and expertise in the safe and effective treatment of ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... “Dr. Google” before calling a physician. In an effort to share more and ... care provider in Pennsylvania to publicly share patient satisfaction ratings and comments about ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mesothelioma researchers in Australia have ... may be a viable option. Surviving Mesothelioma has just posted an article on ... surgeons at the University of New South Wales, peritoneal mesothelioma patients ...
(Date:8/4/2015)... Las Vegas, Nevada (PRWEB) , ... August 04, ... ... INTIMATELY FEMALE, a striking contemporary look at unique artistic expressions from a diverse ... Motel inside the Life Is Beautiful Music & Art Festival on September 25-27, ...
Breaking Medicine News(10 mins):Health News:North Texas Acquisition Press Release 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4
... Net Hospital,Alliance of Florida launched its new Web ... Alliance and links to its member hospitals, as,well ... the 2008,session, and news clips and editorials on ... is designed as a resource for the,public, legislators ...
... program helps Alzheimer,s and dementia patients and ... families regain ... More than 5.2 million Americans,including 250,000 Ohioans, struggle with ... being unveiled in the greater,Cleveland area offers new hope ...
... University, ... University, CENTER VALLEY, Pa., March 24 ... in healthcare,life science and consumer electronics products, today ... Program: Tom Byers, Ph.D. and Tina,Seelig, Ph.D., Stanford ...
... 24 Isolagen(TM), Inc.,(AMEX: ILE ) today announced the ... net. $5.85 million of the sale amount was,paid at the ... next six weeks., "This is an important development for ... facility will enable us to further pursue the,implementation of our ...
... not getting needed screenings for breast and cervical tumors , , ... 32 studies suggests that obese women -- particularly white women ... breast and cervical cancer. , No one knows why ... or Pap smears. And it,s not known why obesity seems ...
... Drugstore Ltd. (NYSE: NPD ) ("China Nepstar" or ... the number of,directly operated stores, today announced that the ... ordinary share of US$0.06 per share, based,on its net ... is payable on,or around May 12th, 2008, to shareholders ...
Cached Medicine News:Health News:Cleveland Area Homewatch CareGivers Unveil New Alzheimer's Program 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 2Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 3Health News:Olympus Announces 2008 Winners of Olympus Innovation Awards 4Health News:Isolagen, Inc. Sells Switzerland Facility 2Health News:Isolagen, Inc. Sells Switzerland Facility 3Health News:Obese Women Less Likely to Be Tested for Some Cancers 2Health News:China Nepstar Chain Drugstore Announces Dividend 2Health News:China Nepstar Chain Drugstore Announces Dividend 3
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... peptic ulcers are caused by H. pylori ... while the patient is still present with ... of waived or non-waived laboratories.,The Right Choice ... rapid H. pylori test available; helps to ...
... CHECK 02 PLUS CONCENTRATOR ANALYZER Now there ... the operating parameters necessary for performing concentrator ... ™, an efficient and cost-effective analyzer designed ... concentration (%), flow rate (L-min), and patient ...
... Exclusively for the Japanese market:, ... advanced, low-sound level, low-power-consumption, high-performance oxygen ... settings., ,Offered in an attractive, ... was specifically designed to meet the ...
Medicine Products: